Engineered immune cells take on advanced stomach cancer in new trial
NCT ID NCT07538856
First seen Apr 26, 2026 · Last updated May 23, 2026 · Updated 5 times
Summary
This early-stage trial is testing a new treatment called CT0494BCP for people with advanced stomach or gastroesophageal junction cancer who have already tried other treatments. The therapy uses specially engineered immune cells (CAR-T cells) to attack the cancer. The study will enroll 50 adults aged 18-70 to find the safest dose and see if the treatment can shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC / GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
BeijingGoBroadH
Beijing, Beijing Municipality, 10000, China
Conditions
Explore the condition pages connected to this study.